An inhaled treatment delivered directly to your lungs
ARIKAYCE is an inhaled antibiotic you take with a nebulizer. It is different from other inhaled antibiotics because the amikacin is contained inside tiny particles called liposomes. These liposomes are designed to help the medicine reach the lungs.
The inhaled, liposomal formulation of ARIKAYCE targets MAC bacteria within the lungs, giving you a different way to fight MAC lung disease
How does ARIKAYCE work?
When you inhale ARIKAYCE, the liposomes containing the medicine travel into your lungs. There, they enter the body's cells, called macrophages, where the MAC bacteria can live. Once inside the lungs, they release the medicine to fight the infection.
Watch the video below to see ARIKAYCE in action.
Studied in patients who did not respond to other treatments
Living with MAC lung disease can be challenging. You may have tried treatments in the past and not seen results. ARIKAYCE was developed for people like you.
ARIKAYCE + combination antibacterial drug treatment plan was studied in 224 patients with MAC lung disease who either stopped responding or never responded to their previous treatment.
One of the key goals of treating MAC lung disease is culture conversion. Culture conversion means you no longer test positive for MAC bacteria in your lungs.
In the ARIKAYCE clinical study, culture conversion was defined as being free of a MAC infection for 3 months in a row, as seen in monthly cultures. Culture conversion had to be achieved within the first 6 months.
Additional measures evaluated in the ARIKAYCE study included:
- Improvement in the distance walked after 6 minutes (6-minute walk test)
- Improvement in response to the St George's Respiratory Questionnaire, designed to measure impact on overall health, daily life, and perceived well-being in patients with lung disease
More ARIKAYCE patients tested negative for MAC lung disease
after taking ARIKAYCE + combination
antibacterial drug treatment plan
In the ARIKAYCE clinical study, 3X as many patients tested negative for MAC lung disease after taking ARIKAYCE + combination antibacterial drug treatment plan compared to those taking a combination antibacterial drug treatment alone (29.0% [65/224] vs 8.9% [10/112]).
4X as many patients treated with ARIKAYCE + combination antibacterial drug treatment plan remained negative for MAC lung disease compared to those treated with a combination antibacterial drug treatment alone (27.7% [62/224] vs 6.3% [7/112]).
Among those who tested negative, 95.4% of patients treated with ARIKAYCE + combination antibacterial drug treatment plan were still culture negative at 6 months compared to 70% of patients taking combination antibacterial drug treatment alone (62/65 vs 7/10).
In the ARIKAYCE clinical study, there was no improvement in the 6-minute walk test and St George's Respiratory Questionnaire measurements at the end of 6 months.